PHARMACY

Athlete’s foot spreading rapidly, roundtable of medical professionals concludes

BY Alaric DeArment

LOS ANGELES The incidence of tinea pedis, commonly known as athlete’s foot, is growing exponentially in the United States and may cause serious complications if not properly diagnosed and treated, physicians participating in a roundtable discussion in Los Angeles recently said.

In response, OrthoNeutrogena, a division of Johnson & Johnson subsidiary Ortho-McNeil Pharmaceuticals, has released Ertaczo, a prescription anti-fungal ointment. In clinical trials, adverse side effects occurred in 2 percent of patients using the ointment, including contact dermatitis, dry skin, burning skin, application site reaction and skin tenderness.

The active ingredient of Ertaczo is sertaconazole.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

HealthPartners site helps Minneapolis area patients estimate healthcare costs

BY Alaric DeArment

BLOOMINGTON, Minn. A healthcare organization has launched a Web site that quotes prices for 83 procedures at the primary care and radiology centers in its network in the Minneapolis-St. Paul metropolitan area.

HealthPartners announced the launch Tuesday. The price listings are in the ?Find a Provider/Clinic? section of its Web site, www.healthpartners.com.

The prices listed are for five high-volume service categories, including office visits, immunizations and vaccines, lab services, X-rays and CTs and MRIs. For example, a wrist X-ray at one of the clinics costs $61.60, while an influenza test costs $29.18.

“This is an important step forward in transparency because the information we provide is for specific prices rather than a range,” HealthPartners senior vice president for customer service and product innovation Scott Aebischer said. “This information is particularly useful for members who are paying out-of-pocket fees.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA challenges Bayer’s TV commercial claims about Yaz

BY Alaric DeArment

NEW YORK The Food and Drug Administration told Bayer in a letter Tuesday that two of the company’s TV commercials for its premenstrual dysphoric disorder drug Yaz are misleading.

The FDA said one commercial suggests the drug is approved for treating post-menopausal syndrome by saying it treats irritability, moodiness and bloating—symptoms common to PMDD and PMS. That commercial, which featured women hitting balloons while singing “We’re not gonna take it,” has been pulled.

The second commercial had the song “Good-Bye to You” and women releasing balloons with symptoms written on them. The FDA said evidence has not demonstrated that Yaz eliminates symptoms, even though the commercial suggests that it does.

Yaz (drospirenone and ethinyl estradiol) had global sales of $1.42 billion in 2007, according to Bayer financial data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?